Goldman Sachs’s Galmed Pharmaceuticals GLMD Stock Holding History

Goldman Sachs’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-18	Closed	-$91K	–	6323
2021 Q1	$91K	Buy	+18	New	+$99.6K	﹤0.01%	5861
2020 Q2	–	Sell	-12	Closed	-$62K	–	5308
2020 Q1	$62K	Buy	+12	New	+$91.2K	﹤0.01%	5017
2019 Q2	–	Sell	-12	Closed	-$138K	–	5210
2019 Q1	$138K	Buy	+12	New	+$140K	﹤0.01%	4876
2016 Q2	–	Sell	-8	Closed	-$58K	–	7105
2016 Q1	$58K	Sell	8 -2	-20%	-$15.7K	﹤0.01%	6353
2015 Q4	$115K	Sell	10 -14	-58%	-$179K	﹤0.01%	6098
2015 Q3	$253K	Sell	24 -5	-17%	-$65.8K	﹤0.01%	5768
2015 Q2	$422K	Sell	29 -4	-12%	-$55.7K	﹤0.01%	5373
2015 Q1	$445K	Hold	33	–	–	﹤0.01%	5259
2014 Q4	$273K	Buy	33 +24	+267%	+$209K	﹤0.01%	5878
2014 Q3	$117K	Buy	+9	New	+$98.4K	﹤0.01%	6510

Other funds holding GLMD

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $131M AUM 35.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Goldman Sachs's GLMD Position: Q2 2021 in Review

Goldman Sachs sold out of Galmed Pharmaceuticals (GLMD) in Q2 2021, closing a stake of 18 shares — an estimated $91K sold.

Goldman Sachs first reported a position in GLMD in Q3 2014 and held it in 10 quarters. The position peaked at $445K in Q1 2015. 22 funds tracked by Wall St. Rank hold GLMD as of Q2 2021.

Goldman Sachs reported no remaining Galmed Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Goldman Sachs sold 18 Galmed Pharmaceuticals shares in Q2 2021, an estimated $91K.
Goldman Sachs first reported a position in Galmed Pharmaceuticals in Q3 2014 and held it in 10 quarters.
Goldman Sachs's Galmed Pharmaceuticals position peaked at $445K in Q1 2015.
22 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2021.

Based on Goldman Sachs's 13F filing for Q2 2021, filed 13 Aug 2021.